FINANCIAL TRUST COMPANY INC
For the Period ♦11112 to 413W12
Note P indicates position adjusted for Pending Trade Activity.
Unrealized GainiLoss is shown as "N A" in cases where we do not have appropriate cost information for all lax lots comprising the position. Please contact your J P Morgan team for additional
information.
Equity Detail
Adjusted Tax Cost Unrealized Est. Annual Inc
Price Quality Value Original Cost Gain/Loss Accrued Div. Yield
US Large Cap Equity
ARIAD PHARMACEUTICALS INC 16.30 16,535.000 269,520.50 251,475.52 18,044.96
04033A-10-0 ARIA
BIDDEN IDEC INC 134.01 2.095 000 280 750 95 250,454.95 30,296.00
09062X-10-3 BIIB
DB CONT BUFF EQ MS 08/07/12 81.37 1000000,000 813,700.00 1,000,000.00 (186,300.00)
25% CONTIN BARRIER- 13%CPN
30% CAP
INITIAL LEVEL-07)1511 MS.21.09
2515A1-A7-6
HSBC MARKET PLUS SPX 06/17113 101.67 5,000,000.000 5,083,500.00 5,000,000.00 83,500.00
72% KO BARRIER- 0%CPN
,UNCAPPED
INITIAL LEVEL-0211N12 SPX:1350.50
4042K1-XQ-1
SO MARKET PLUS SPX 02107/13 108.93 2,000,000.000 2.178,600 00 2,000,000 00 178,600.00
75% CONTIN BARRIER- 6.25%CPN
,UNCAPPED
INITIAL LEVEL-08/03/11 SPX:1.260.34
78423A-2Y-7
Total US Large Cap Equity $8.626.071.45 $8.501.930.47 3124.140.98 S0.00 0.00%
JP Morgan Acco LIne Page 5 of 26 Consolidated Statement Page 8
Confidential Treatment Requested by JPMorgan JPM-SDNY-000 15830
Chase
CONFIDENTIAL SDNY_GM_00285028
EFTA01493007